A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece

AbbVie

Status: Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia

Study type: Observational

Funder types: Industry

Identifiers

NCT04159779

P19-568

Details and patient eligibility

About

This study is being done to evaluate the clinical outcomes of Chronic Lymphocytic Leukemia (CLL) participants treated with venetoclax as routine standard of care in Greece. The decision to treat with venetoclax is made by the participant's physician prior to being offered enrollment in this study.

The objectives of this study include determining overall response rate, assessing safety information, analyzing patient profiles and disease characteristics and participant quality of life.

Enrollment: 180 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
• Eligible to receive venetoclax as per local label
• Physician has decided to initiate CLL treatment with venetoclax and the decision to treat is made by the physician in accordance with the local label prior to any decision to approach the participant about the study
• Participant has been fully informed verbally and in writing about the study and does not object to their data being processed or subjected to data quality control

Exclusion criteria

• Prescribed or treated with venetoclax outside of marketing authorization
• Currently participating in, or previously participated within 30 days prior to venetoclax start, in any other interventional clinical trial

Trial design

180 participants in 1 patient group

Venetoclax Participants

Description:

Participants for whom the treating physician has decided to treat with venetoclax before enrollment in this study.